With a view on precautions for use in renal and hepatic impairment, in our cohort RDV was administered in 1.9% (21/1113) patients suffering from chronic kidney disease with a glomerular filtration rate (GFR) below 30 ml/min or dialysis and in 0.3% (3/1011) patients with ALT elevations > 5 × upper limit of normal (ULN) at first SARS-CoV-2 detection. Here, GPT is linked to chronic kidney disease.